Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. News
  7. Press Releases
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
CommuniquÚs de presse de la sociÚtÚ TRANSGENE
05/27BIOINVENT INTERNATIONAL : and Transgene receive IND approval from the U.S. FDA for BT-001,..
AQ
04/27TRANSGENE : April 27, 2021 - Transgene reports business update and end Q1 2021 financial p..
PU
04/12TRANSGENE : April 12, 2021 - Transgene Announces Upcoming Investor Meetings
PU
04/09TRANSGENE : April 9, 2021 - Transgene presents initial Phase I data of TG6002, highlightin..
PU
04/07TRANSGENE : April 7, 2021 - Availability of Preparatory Documents for the Combined General..
PU
04/01TRANSGENE : April 1, 2021 - Availability of Transgene's 2020 Universal Registration Docume..
PU
03/10TRANSGENE : Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination W..
BU
03/10TRANSGENE : Significant Milestones Achieved on All Drug Candidates in 2020 and Financial V..
BU
03/09TRANSGENE : March 10, 2021 - Significant milestones achieved on all drug candidates in 202..
PU
03/09TRANSGENE : March 10, 2021 - Transgene expands Phase II clinical trial of therapeutic vacc..
PU
03/02TRANSGENE : to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences
BU
03/01TRANSGENE : March 2, 2021 - Transgene to Present its Immuno-Oncology Expertise at Upcoming..
PU
03/01BIOINVENT INTERNATIONAL : and Transgene has enrolled first patient in Phase I/IIa trial of..
AQ
03/01TRANSGENE : and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncoly..
BU
01/21TRANSGENE : January 21, 2021 - First Head & Neck Cancer Patient Treated in France in a Pha..
PU
01/21TRANSGENE : First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4..
BU
01/19TRANSGENE : January 19, 2021 - Transgene and BioInvent receive approval from ANSM to proce..
PU
01/19TRANSGENE : and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of ..
BU
01/15TRANSGENE : January 14, 2021 - Transgene Appoints Gaëlle Stadtler as Director of Human Res..
PU
01/14TRANSGENE : Appoints Gaëlle Stadtler as Director of Human Resources
BU
01/06TRANSGENE : at June 30, 2020
PU
01/06TRANSGENE : Report on the Transgene Liquidity Contract with Natixis Oddo BHF SCA as of Dec..
BU
2020TRANSGENE : December 21, 2020 - Transgene and BioInvent receive CTA approval for Phase 1/2..
PU
2020TRANSGENE : and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-..
BU
2020TRANSGENE : Announces Financial Calendar for 2021
BU
2020TRANSGENE : December 16, 2020 - Transgene Announces Investor Meetings for January 2021
PU
2020TRANSGENE : Announces Investor Meetings for January 2021
BU
2020TRANSGENE : December 3, 2020 - Transgene to present Phase 1b/2 trial results of TG4001 in ..
PU
2020TRANSGENE : to Present Phase 1b/2 Trial Results of TG4001 in Combination with avelumab in ..
BU
2020TRANSGENE : December 3, 2020 - Transgene appoints Hedi Ben Brahim as Chairman and Chief Ex..
PU
2020TRANSGENE : Appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
BU
2020TRANSGENE : And BioInvent Present Data on Next Generation Oncolytic Virus BT-001 at the SI..
BU
2020TRANSGENE : November 9, 2020 - Transgene presents e-poster outlining detailed results from..
PU
2020TRANSGENE : Presents E-Poster Outlining Detailed Results from the Phase 1b/2 Trial of TG40..
BU
2020TRANSGENE : November 5, 2020 - Transgene reports business update and end Q3 2020 financial..
PU
2020TRANSGENE : Reports Business Update and End Q3 2020 Financial Position
BU
2020TRANSGENE : Presents Its Individualized Immunotherapy, TG4050, at The Annual Neoantigen Ba..
BU
2020TRANSGENE : October 27, 2020 - Transgene announces detailed results from clinical study of..
PU
2020TRANSGENE : Announces Detailed Results From Clinical Study of TG4001 in Combination With A..
BU
2020TRANSGENE : October 19, 2020 - Acceptance of Late Breaking Abstract at Upcoming SITC 2020 ..
PU
2020TRANSGENE : Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The ..
BU
2020TRANSGENE : and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniv..
BU
2020TRANSGENE : NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical T..
AQ
2020TRANSGENE : October 6, 2020 - Transgene, NEC and BostonGene Announce Strategic Collaborati..
PU
2020TRANSGENE : NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical T..
BU
2020TRANSGENE : September 16, 2020 - Positive clinical results for TG4001 and TG6002 and finan..
PU
2020TRANSGENE : Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secur..
BU
2020TRANSGENE : Availability of the Half-year Financial Report as of June 30, 2020
BU
2020TRANSGENE : September 9, 2020 - Transgene Announces Upcoming Investor Meetings
PU
2020TRANSGENE : Announces Upcoming Investor Meetings
BU
2020TRANSGENE : September 8, 2020 - Positive initial data from a Phase 1 trial with Transgene'..
PU
2020TRANSGENE : Positive Initial Data From a Phase 1 Trial With Transgene's Oncolytic Virus TG..
BU
2020TRANSGENE : August 4, 2020 - Transgene Receives $22.2 million from the Sale of Part of its..
PU
2020TRANSGENE : Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly Bi..
BU
2020TRANSGENE : Reports Results From Clinical Study of TG4001 in Combination With Avelumab in ..
BU
2020TRANSGENE : July 22, 2020 - Transgene Reports Results from Clinical Study of TG4001 in Com..
PU
2020TRANSGENE : July 9, 2020 - Transgene and Hypertrust Patient Data Care announce successful ..
PU
2020TRANSGENE : and Hypertrust Patient Data Care Announce Successful Go-Live of the World's Fi..
BU
2020TRANSGENE : Half-Year Report on the Transgene Liquidity Contract with Natixis Oddo
BU
2020TRANSGENE : Presents Promising New Data from its Next-Generation Immunotherapy Platforms a..
BU
2020TRANSGENE : 's and BioInvent's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical..
BU
2020TRANSGENE : May 27, 2020 - Combined General Meeting of May 27, 2020
PU
2020TRANSGENE : Combined General Meeting of May 27, 2020
BU
2020TRANSGENE : May 15, 2020 - Transgene and BioInvent present preclinical data demonstrating ..
PU
2020TRANSGENE : and BioInvent Present Preclinical Data Demonstrating BT-001's Powerful Activit..
BU
2020TRANSGENE : May 15, 2020 - Transgene and NEC demonstrate high accuracy of AI-based neoanti..
PU
2020TRANSGENE : and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction for the De..
BU
2020TRANSGENE : May 6, 2020 - Transgene reports Q1 2020 financial position and business update
PU
2020TRANSGENE : Reports Q1 2020 Financial Position and Business Update
BU
2020TRANSGENE : May 4, 2020 - Vaxxel acquires Transgene's DuckCelt«-T17 cell line to develop i..
PU
2020TRANSGENE : Vaxxel Acquires Transgene's DuckCelt«-T17 Cell Line to Develop Industrial-scal..
BU
2020TRANSGENE : Availability of Preparatory Documents for the Combined General Meeting of May ..
BU
2020TRANSGENE : April 3, 2020 - Availability of Preparatory Documents for the Combined General..
PU
2020TRANSGENE : Availability of Transgene's 2019 Universal Registration Document and Update on..
BU
2020TRANSGENE : March 11, 2020 - Major R&D milestones achieved in 2019 and strong clinical act..
PU
1  2  3  4Next
Upcoming event on TRANSGENE